United Therapeutics (NASDAQ:UTHR) EVP Sells $4,690,247.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, November 19th. The shares were sold at an average price of $565.09, for a total value of $4,690,247.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $25,526,245.48. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $554.73 on Friday. United Therapeutics Corporation has a 52 week low of $455.63 and a 52 week high of $614.23. The company’s fifty day moving average is $550.00 and its 200-day moving average is $538.90. The company has a market capitalization of $23.63 billion, a PE ratio of 20.93, a P/E/G ratio of 3.69 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. During the same quarter last year, the business earned $7.16 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 25.08 EPS for the current year.

United Therapeutics declared that its board has approved a share buyback plan on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This repurchase authorization permits the biotechnology company to reacquire up to 8.3% of its shares through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Toth Financial Advisory Corp increased its position in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new position in shares of United Therapeutics in the second quarter worth about $30,000. Gen Wealth Partners Inc bought a new position in shares of United Therapeutics in the third quarter worth about $34,000. Caitlin John LLC bought a new position in shares of United Therapeutics in the second quarter worth about $37,000. Finally, PFS Partners LLC acquired a new position in shares of United Therapeutics during the third quarter worth approximately $45,000. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $700.00 to $703.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. JPMorgan Chase & Co. cut their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. HC Wainwright began coverage on United Therapeutics in a report on Monday, November 9th. They issued a “buy” rating and a $660.00 target price on the stock. TD Cowen increased their price target on United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $368.00 price target on shares of United Therapeutics in a research report on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.

Read Our Latest Research Report on UTHR

Latest United Therapeutics News

Here’s some of the latest news about UTHR:

  • Positive Sentiment: The first clinical UThymoKidney transplant advances United Therapeutics’ effort to develop an additional source of transplantable kidneys. Progress in the trial could support the long-term value of its xenotransplantation program, though clinical and regulatory risks remain. Article: First clinical xenotransplant in EXTEND study
  • Neutral Sentiment: One article argues UTHR may be below fair value after the transplant announcement. That is an opinion-based valuation view, not a new financial forecast or clinical result. Article: UTHR may be below fair value
  • Negative Sentiment: Recent insider-sale reports may weigh on sentiment: CEO Martine Rothblatt sold 5,410 shares for about $3.13 million, while EVP Paul Mahon sold 8,300 shares for about $4.69 million. Rothblatt retained 324,443 shares after her sale; the transactions alone do not establish a change in the company’s outlook. Article: CEO share sale

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Articles

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.